SRF and hepatocellular carcinoma: Most important, significantly higher LATS1 mRNA expression was found in Srf non-responders as compared with Srf responders after Srf treatment (Fig. 1l, right panel), suggesting that LATS1 mRNA levels may represent a new biomarker to predict Srf response in HCC patients.